NCT Number: NCT00120055
Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity
The aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared to healthy controls.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
About this study
A 24 hour pharmacokinetic investigation of atorvastatin and metabolites will be performed in 15 patients with a history of atorvastatin -induced myotoxicity. The possible link to relevant mutations in SLCO1B1, CYP3A5 and MDR1 will be also be investigated
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- above 18 years
- previous history of atorvastatin-associated myotoxicity
Exclusion criteria
- current treatment with drugs or herbal remedies with known pharmacokinetic interaction potential with atorvastatin
- previous CK levels above ten times the upper limit of normal range
- pregnancy and persistent muscular complaints after a four week wash-out period of statin treatment
Treatment and study plan
Primary outcomes
-
Statin toxicity
Time frame: 1 year
Rechallenge test of statin induce toxicity
Sponsors and collaborators
Lead sponsor
University of Oslo School of Pharmacy
Other
Registry information
Important dates
- Study start
- 2005
- Study completion
- 2005
- First posted
- Jul 14, 2005
- Registry last updated
- Dec 3, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Differential SERCA Expression in Laryngeal Muscles
NCT06837467
Muscular Diseases, Musculoskeletal Diseases
Sohag, Egypt
View Trial DetailsInnovative Ultrasound Technology in Neuromuscular Disease
NCT02104921
Accidental Injuries, Amyotrophic Lateral Sclerosis
Boston, Massachusetts, United States
View Trial DetailsIdentification of Tongue Involvement in Late-Onset Pompe Disease
NCT02765828
Brain Diseases, Brain Diseases, Metabolic
Durham, North Carolina, United States
View Trial DetailsPeripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies
NCT03751644
Atrial Remodeling, Connective Tissue Diseases
São Paulo, Brazil
View Trial Details